Prurigo Nodularis Pipeline Analysis: 5+ Pipeline Therapies and 5+ Key Companies are Looking Out in the Prurigo Nodularis Pipeline Landscape

July 02 18:45 2021
Prurigo Nodularis Pipeline Analysis: 5+ Pipeline Therapies and 5+ Key Companies are Looking Out in the Prurigo Nodularis Pipeline Landscape

Prurigo Nodularis Pipeline
There are currently 5+ drugs in the pipeline for Prurigo Nodularis treatment

The Prurigo Nodularis pipeline report from DelveInsight provides comprehensive insights into 5+ companies and 5+ pipeline drugs in the Prurigo Nodularis pipeline landscape. It includes clinical and nonclinical stage products in the pipeline drug profiles. It also assesses therapeutics based on product type, stage, route of administration, and molecule type.

Some of the Important Finding from the Prurigo Nodularis Pipeline Report

  • Sanofi and Regeneron Pharmaceuticals initiated a Phase III clinical trial in January 2020 to assess the efficacy and safety of dupilumab in Prurigo Nodularis patients.

  • Chugai Pharmaceutical and Galderma Pharma S.A. announced in July 2016 that they had signed a global licence deal for the drug “Nemolizumab” (CIM331), which is currently in Phase III clinical trials for Prurigo Nodularis.

  • Kiniksa Pharmaceuticals announced the results of Prurigo Nodularis phase II clinical trials for Vixarelimab (KPL-716) in April 2020. 

  • Some pipeline therapies such as Haduvio, and others are in the Phase II/III of Prurigo Nodularis clinical trials.

  • Key players in Prurigo Nodularis pipeline landscape include Sanofi, Regeneron Pharmaceuticals, Chugai Pharmaceutical, Galderma Pharma S.A., Kiniksa Pharmaceuticals, Trevi Therapeutics, and others. 

For more information, request sample @ Prurigo Nodularis Treatment

Prurigo Nodularis: Overview

Prurigo Nodularis (PN) is a chronic, inflammatory skin condition marked by pruritic nodules that have a significant negative influence on one’s quality of life. A cutaneous reaction pattern caused by vicious cycles of chronic itch followed by recurrent scratching is assumed to constitute the pathogenesis of Prurigo Nodularis. The specific pathophysiology of Prurigo Nodularis is still unknown.

Prurigo Nodularis Treatment 

Treatment for Prurigo Nodularis demands a diverse approach. Patients should be educated on how to reduce scratching of lesions, how to diagnose and treat underlying causes of pruritus, and how to diagnose and treat any psychiatric disorders linked to scratching and picking at skin. Topical and systemic treatments are aimed at breaking the itch-scratch cycle.

Prurigo Nodularis Pipeline Analysis: Drug Profiles 

Dupilumab: Regeneron/Sanofi

Product Description

Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is an immunoglobulin G4 subclass human monoclonal antibody that inhibits IL-4 and interleukin-13 (IL-13) signalling by binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.

Phase III

NCT04202679 (PRIME 2): Sanofi launched a Phase 3 randomised, double-blind, placebo-controlled, multi-center, parallel group study in January 2020 in collaboration with Regeneron Pharmaceuticals to assess the efficacy and safety of dupilumab in patients with Prurigo Nodularis who are inadequately controlled on topical prescription therapies or for whom those therapies are not advisable.

Get in touch to know more about PN @ Prurigo Nodularis ICD 10

Prurigo Nodularis Pipeline Therapies and Key Companies 

  • Vixarelimab: Kiniksa Pharmaceuticals

  • Haduvio: Trevi Therapeutics

  • Dupilumab: Regeneron/Sanofi

  • Nemolizumab (CIM331): Chugai Pharmaceutical

Prurigo Nodularis Therapeutics Assessment 

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

    • Protease

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

    • Multiple Kinase Inhibitors

Scope of the Report

Coverage: Global

Prurigo Nodularis Key Players: Kiniksa Pharmaceuticals, Trevi Therapeutics, Regeneron Pharmaceuticals, Sanofi, Chugai Pharmaceutical, Galderma Pharma S.A.,among others

Prurigo Nodularis Pipeline Therapies: Vixarelimab, Haduvio, Dupilumab, Nemolizumab (CIM331), and others

Table of Contents 

1.

Introduction

2.

Executive Summary

3.

Prurigo Nodularis: Overview

4.

Prurigo Nodularis- Analytical Perspective In-depth Commercial Assessment

5.

Prurigo Nodularis Pipeline Therapeutics

6.

Prurigo Nodularis Late Stage Products (Phase III)

7.

Prurigo Nodularis Mid Stage Products (Phase  II/III)

8.

Prurigo Nodularis Mid Stage Products (Phase  II)

9.

Prurigo Nodularis Early Stage Products (Phase  I/II and Phase I)

10.

Prurigo Nodularis Pre-clinical and Discovery Stage Products

11.

Prurigo Nodularis Therapeutic Assessment

12.

Prurigo Nodularis Inactive Products

13.

Prurigo Nodularis Company-University Collaborations (Licensing/Partnering) Analysis

14.

Prurigo Nodularis Key Companies

15.

Prurigo Nodularis Key Products

16.

Prurigo Nodularis- Unmet Needs

17.

Prurigo Nodularis- Market Drivers and Barriers

18.

Prurigo Nodularis- Future Perspectives and Conclusion

19.

Prurigo Nodularis Analyst Views

20.

Appendix

21.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key questions answered in the Prurigo Nodularis Pipeline Report

  • What are the treatment options for Prurigo Nodularis?

  • How many pharmaceutical companies are working on therapies for Prurigo Nodularis?

  • What are the most popular therapies from each of these companies?

  • How many Prurigo Nodularis drugs does each company generate in total?

  • How many Prurigo Nodularis pipeline drugs are in the early stages of development, mid-stage development, or late-stage development?

  • How many of the in-development therapies can be used alone or in combination with other treatments?

  • What are the most important industry-industry and industry-academy cooperation, mergers and acquisitions, and licencing practises that have an impact on Prurigo Nodularis?

Related Reports

Pruritus Pipeline Insights

Get comprehensive analysis of Pruritus pipeline therapies and key companies including Cara Therapeutics, Regeneron, AbbVie, Atridia, Saniona, DermaXon, Trevi Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gorakhpurreporter.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7